HighPoint Advisor Group’s Autolus Therapeutics AUTL Stock Holding History

HighPoint Advisor Group’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$91.2K	Sell	57,000 -10,000	-15%	-$15.7K	﹤0.01%	686
2026 Q1	$92.5K	Sell	67,000 -72,800	-52%	-$111K	﹤0.01%	639
2025 Q4	$278K	Buy	139,800 +51,500	+58%	+$79.1K	0.01%	881
2025 Q3	$144K	Sell	88,300 -20,320	-19%	-$39.7K	0.01%	670
2025 Q2	$248K	Buy	108,620 +29,500	+37%	+$48.8K	0.01%	582
2025 Q1	$104K	Buy	79,120 +500	+0.6%	+$1.01K	0.01%	637
2024 Q4	$150K	Buy	+78,620	New	+$266K	0.01%	643

Other funds holding AUTL

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

HighPoint Advisor Group's AUTL Position: Q2 2026 in Review

HighPoint Advisor Group reduced its Autolus Therapeutics (AUTL) stake by 15% in Q2 2026, selling an estimated $15.7K and leaving 57,000 shares worth $91.2K. The position accounts for ﹤0.01% of the portfolio, ranked #686.

HighPoint Advisor Group first reported a position in AUTL in Q4 2024 and has held it in 7 quarters since. The position peaked at $278K in Q4 2025. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

HighPoint Advisor Group held 57,000 shares of Autolus Therapeutics worth $91.2K as of Q2 2026.
HighPoint Advisor Group sold 10,000 Autolus Therapeutics shares in Q2 2026, an estimated $15.7K.
Autolus Therapeutics made up ﹤0.01% of HighPoint Advisor Group's portfolio in Q2 2026, its #686 holding.
HighPoint Advisor Group first reported a position in Autolus Therapeutics in Q4 2024 and has held it in 7 quarters since.
HighPoint Advisor Group's Autolus Therapeutics position peaked at $278K in Q4 2025.
84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on HighPoint Advisor Group's 13F filing for Q2 2026, filed 5 Aug 2026.